Physician profile
Souzan E El-Eid
NPI 1841289444
$5,215.86
in general payments reported to CMS, 2019-2025
27 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $1,103 · 2021: $677 · 2022: $424 · 2023: $410 · 2024: $988 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,820.57 | 2019-2024 | Encor |
| Daiichi Sankyo INC. | $684.57 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals Lp | $593.68 | 2021-2024 | Imfinzi |
| Focal Therapeutics, INC. | $355.89 | 2019-2020 | |
| Sirius Medical Systems | $324.55 | 2024 | Pintuition |
| Lilly USA, LLC | $274.09 | 2022-2024 | Jaypirca, Verzenio |
| Hologic INC | $211.42 | 2020 | |
| Merck Sharp & Dohme LLC | $172.24 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Smith+Nephew, INC. | $130.49 | 2022 | |
| Tempus Ai, INC | $117.45 | 2024 | |
| Sobi, INC | $73.44 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $65.56 | 2024-2025 | |
| Janssen Biotech, INC. | $54.13 | 2025 | Rybrevant, Erleada |
| Emd Serono, INC. | $39.79 | 2025 | |
| Olympus America INC. | $34.91 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $31.85 | 2019-2020 | |
| Genentech USA, INC. | $29.74 | 2023 | Polivy, Phesgo, Perjeta |
| Abbvie INC. | $28.52 | 2024 | |
| Dilon Technologies, INC. | $27.97 | 2023 | Hemoblast Bellows |
| Celgene Corporation | $22.41 | 2022 | |
| Genmab U.S., INC. | $21.34 | 2025 | Epkinly |
| Eisai INC. | $19.48 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.45 | 2024 | Fruzaqla |
| Medtronic USA, INC. | $17.06 | 2019 | |
| Glaxosmithkline, LLC. | $15.57 | 2025 | Ojjaara |
| Seagen INC. | $14.96 | 2023 | Tukysa |
| Mirati Therapeutics, INC. | $14.73 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Souzan El-Eid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.